TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03285165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
Description: patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
Description: patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-70 mcg/kg/h propofol infusion.
Description: Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-70 mcg/kg/h propofol infusion.
Description: Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
Study: NCT04796207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil (DPA+EPA 2:1 ratio) Capsules
Description: The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Safflower Oil Capsules
Description: The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
Study: NCT02759835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Ablative Therapy (LAT)
Description: local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
Study: NCT04086238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU
Study: NCT01313169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Reminder
Description: EMR reminders displayed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Reminder + Panel management
Description: EMR Reminder + Panel management
Study: NCT01356563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Description: Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
Study: NCT02759835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Ablative Therapy (LAT)
Description: local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
Study: NCT04016272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
Study: NCT01586481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SANIDIAB
Description: off-loading shoe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAROUK
Description: old shoe
Study: NCT03617289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W
Study: NCT02309671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Study: NCT04583644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion Surgery
Description: Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation.
Study: NCT03546816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg Serlopitant Tablets
Description: Serlopitant Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo Tablets
Study: NCT04434001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate Human
Description: Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
Study: NCT03509246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin plus Bortezomib
Description: Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
Study: NCT01126320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100,
Description: Respiratory guard system during mechanical ventilation with routine mechanical ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine mechanical ventilator
Description: routine mechanical ventilation
Study: NCT01096576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balapiravir [RO4588161]
Description: sequential cohorts receiving doses orally twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally twice daily for 5 days
Study: NCT04196543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: écho-doppler with ultrasonar Sonovue® injection
Description: During this unique visit they will benefit from 2 imaging exams performed by two different operators:~* Echo-doppler without standard method contrast injection (common practice)~* An echo-doppler with Sonovue® ultrasound injection Ultra_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later.
Study: NCT02058836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injection
Description: One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
Study: NCT00528671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenprocoumon
Description: The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenprocoumon
Description: The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenprocoumon
Description: The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
Study: NCT00835185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8 (necitumumab)
Description: IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid (FA)
Description: FA 400 mg/m² IV infusion bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
Study: NCT01236352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543
Study: NCT05846698

Intervention type: DRUG
Intervention: Luo-Bu-Fu-Ke-Bi-RI Pill
Description: 10 pills twice daily

Intervention type: DRUG
Intervention: tibolone
Description: 2.5 mg once daily
Study: NCT02858232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Study: NCT02787083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Study: NCT02031536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT04718636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)
Description: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Daily
Study: NCT00322686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oglemilast
Description: Oglemilast, 15mg oral administration, once per day and then dose-matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Oglemilast
Description: Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
Study: NCT00610727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.5 mg IV over 5 sec
Description: IV Prochlorperazine for bioavailability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 0.625 mg
Description: Inhaled Staccato Prochlorperazine 0.625 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 1.25 mg
Description: Inhaled Staccato Prochlorperazine 1.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 2.5 mg
Description: Inhaled Staccato Prochlorperazine 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 5 mg
Description: InhaledStaccato Prochlorperazine 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 10 mg
Description: InhaledStaccato Prochlorperazine 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled Staccato Placebo (0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg IV over 5 sec
Description: Prochlorperazine 10 mg IV over 5 sec for patient qualification
Study: NCT04492813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic of propofol and remifentanil
Description: Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic of propofol and remifentanil
Description: Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
Study: NCT04069585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA® Redensity with new anesthetic agent
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA® Redensity with lidocaine
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
Study: NCT04944498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Tarsorrhaphy
Description: A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gold Weight Implant
Description: Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess
Study: NCT00799955

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block
Description: 100 micrograms of spinal morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided TAP block
Description: 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
Study: NCT00136279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linking Lives parent-based intervention
Description: Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linking Lives parent-based intervention
Description: Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linking Lives parent-based intervention
Description: Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
Study: NCT02891642

Intervention type: DEVICE
Intervention: Immunomagnetic Detection
Description: Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
Study: NCT03176004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: A computer game is used to facilitate attention away from threatening words.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: A computer game is used to facilitate attention away from threatening words.
Study: NCT01267240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02787083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00094523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: Fosamprenavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: Fosamprenavir
Study: NCT02305524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: Intubation using ETView VivaSight SL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: Intubation using ETView VivaSight SL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation with macintosh laryngoscope with conventional tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation with macintosh laryngoscope with conventional tube
Study: NCT00691561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ABLE
Description: Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
Study: NCT00069823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor 40 mg orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo proton pump inhibitor
Description: Placebo proton pump inhibitor
Study: NCT02801981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2230672
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2230672
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2230672
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2230672
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
Study: NCT00187278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing
Description: Biventricular Pacemaker implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV Pacing
Description: Standard Pacemaker implant
Study: NCT02868736

Intervention type: DEVICE
Intervention: Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test